Condition
HSV Infection
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03073967Phase 3CompletedPrimary
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
NCT05513625Phase 1CompletedPrimary
Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir
NCT06089252Phase 2CompletedPrimary
Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex
NCT01026454Phase 4CompletedPrimary
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
Showing all 4 trials